Jeffrey Dayno compensation by year
Harmony Biosciences Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $414,000 | $431,388 | $445,624 | $458,993 | $612,500 | $715,000 | $743,600 |
| Bonus | $238,050 | $301,972 | $0 | $0 | $200,000 | $300,000 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $1,288,980 | $1,976,520 |
| Option awards | $20,000 | $1,968,249 | $0 | $0 | $3,186,875 | $4,189,508 | $4,599,000 |
| Non-equity incentive | $0 | $0 | $245,093 | $286,870 | $437,000 | $637,000 | $558,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $148 | $885 | $12,027 | $16,289 | $13,919 | $14,683 | $22,415 |
| Total | $672,198 | $2,702,494 | $702,744 | $762,152 | $4,450,294 | $7,145,170 | $7,899,535 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Harmony Biosciences Holdings, Inc. DEF 14A filed April 3, 2026, accession 0001104659-26-039449, and prior-year filings.
How this page was built: the Harmony Biosciences Holdings, Inc. filed document, accession 0001104659-26-039449. Every figure is read from that document and cited to the page and table it appears in. Filed April 3, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 52,000 | $1,945,840 | — |
| RSU | 31,500 | $1,178,730 | — |
| Option | 113,766 | — | $30.69 |
| Option | 180,000 | — | $38.01 |
| Option | 46,875 | — | $35.56 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Harmony Biosciences Holdings, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Harmony Biosciences’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jeffrey Dayno · this page | President and Chief Executive Officer | $7,899,535 |
| Adam Zaeske | Executive Vice President and Chief Commercial Officer | $3,664,228 |
| Sandip Kapadia | Executive Vice President, Chief Financial Officer and Chief Administrative Officer | $3,204,319 |
| Jeffrey Dierks | Former Executive Vice President and Chief Commercial Officer | $2,346,945 |
| Kumar Budur | Executive Vice President and Chief Medical and Scientific Officer | $2,279,439 |
| Andrew Serafin | Executive Vice President and Chief Strategy Officer | $2,009,277 |
Board service
Harmony Biosciences board · FY2023–FY2025How this board is paid
Company policy: Harmony Biosciences pays directors a $50,000 cash retainer and $300,000 in equity. As stated in Harmony Biosciences's FY2025 proxy.
The full Harmony Biosciences compensation record
free company briefThis page is one person within Harmony Biosciences's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Harmony Biosciences proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Harmony Biosciences's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Harmony Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.